|
1
|
Cleator S, Heller W and Coombes RC:
Triple-negative breast cancer: Therapeutic options. Lancet Oncol.
8:235–244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anders CK and Carey LA: Biology,
metastatic patterns, and treatment of patients with triple-negative
breast cancer. Clin Breast Cancer. 9(Suppl 2): S73–S81. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the Carolina
Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Potemski P, Kusinska R, Watala C,
Pluciennik E, Bednarek AK and Kordek R: Prognostic relevance of
basal cytokeratin expression in operable breast cancer. Oncology.
69:478–485. 2005. View Article : Google Scholar
|
|
5
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Masuda H, Zhang D, Bartholomeusz C,
Doihara H, Hortobagyi GN and Ueno NT: Role of epidermal growth
factor receptor in breast cancer. Breast Cancer Res Treat.
136:331–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Furth PA: STAT signaling in different
breast cancer sub-types. Mol Cell Endocrinol. 382:612–615. 2014.
View Article : Google Scholar
|
|
8
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Darnell JE Jr: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thomas SJ, Snowden JA, Zeidler MP and
Danson SJ: The role of JAK/STAT signalling in the pathogenesis,
prognosis and treatment of solid tumours. Br J Cancer. 113:365–371.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang J, Li JZ, Lu AX, Zhang KF and Li BJ:
Anticancer effect of salidroside on A549 lung cancer cells through
inhibition of oxidative stress and phospho-p38 expression. Oncol
Lett. 7:1159–1164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun KX, Xia HW and Xia RL: Anticancer
effect of salidroside on colon cancer through inhibiting JAK2/STAT3
signaling pathway. Int J Clin Exp Pathol. 8:615–621.
2015.PubMed/NCBI
|
|
13
|
Zhang Y, Yao Y, Wang H, Guo Y, Zhang H and
Chen L: Effects of salidroside on glioma formation and growth
inhibition together with improvement of tumor microenvironment.
Chin J Cancer Res. 25:520–526. 2013.PubMed/NCBI
|
|
14
|
Hu X, Zhang X, Qiu S, Yu D and Lin S:
Salidroside induces cell-cycle arrest and apoptosis in human breast
cancer cells. Biochem Biophys Res Commun. 398:62–67. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu X, Lin S, Yu D, Qiu S, Zhang X and Mei
R: A preliminary study: The anti-proliferation effect of
salidroside on different human cancer cell lines. Cell Biol
Toxicol. 26:499–507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Z, Li X, Simoneau AR, Jafari M and Zi
X: Rhodiola rosea extracts and salidroside decrease the growth of
bladder cancer cell lines via inhibition of the mTOR pathway and
induction of autophagy. Mol Carcinog. 51:257–267. 2012. View Article : Google Scholar
|
|
17
|
Trott O and Olson AJ: AutoDock Vina:
Improving the speed and accuracy of docking with a new scoring
function, efficient optimization, and multithreading. J Comput
Chem. 31:455–461. 2010.
|
|
18
|
Hofmann HD and Kirsch M: JAK2-STAT3
signaling: A novel function and a novel mechanism. JAK-STAT.
1:191–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Looyenga BD, Hutchings D, Cherni I,
Kingsley C, Weiss GJ and Mackeigan JP: STAT3 is activated by JAK2
independent of key oncogenic driver mutations in non-small cell
lung carcinoma. PLoS One. 7:e308202012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Byun HJ, Darvin P, Kang DY, Sp N, Joung
YH, Park JH, Kim SJ and Yang YM: Silibinin downregulates MMP2
expression via Jak2/STAT3 pathway and inhibits the migration and
invasive potential in MDA-MB-231 cells. Oncol Rep. 37:3270–3278.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kisseleva T, Bhattacharya S, Braunstein J
and Schindler CW: Signaling through the JAK/STAT pathway, recent
advances and future challenges. Gene. 285:1–24. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Liu A, Hou R, Zhang J, Jia X,
Jiang W and Chen J: Salidroside protects cardiomyocyte against
hypoxia-induced death: A HIF-1α-activated and VEGF-mediated
pathway. Eur J Pharmacol. 607:6–14. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao G, Shi A, Fan Z and Du Y: Salidroside
inhibits the growth of human breast cancer in vitro and in vivo.
Oncol Rep. 33:2553–2560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Björklund M and Koivunen E:
Gelatinase-mediated migration and invasion of cancer cells. Biochim
Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
|
|
25
|
Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F,
Sawaya R and Huang S: Stat3 activation regulates the expression of
matrix metalloproteinase-2 and tumor invasion and metastasis.
Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Darvin P, Baeg SJ, Joung YH, Sp N, Kang
DY, Byun HJ, Park JU and Yang YM: Tannic acid inhibits the
Jak2/STAT3 pathway and induces G1/S arrest and mitochondrial
apoptosis in YD-38 gingival cancer cells. Int J Oncol.
47:1111–1120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nam S, Xie J, Perkins A, Ma Y, Yang F, Wu
J, Wang Y, Xu RZ, Huang W, Horne DA, et al: Novel synthetic
derivatives of the natural product berbamine inhibit Jak2/Stat3
signaling and induce apoptosis of human melanoma cells. Mol Oncol.
6:484–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu Y, Wang L, Wu Y, Lv C, Li X, Cao X,
Yang M, Feng D and Luo Z: Pterostilbene exerts antitumor activity
against human osteosarcoma cells by inhibiting the JAK2/STAT3
signaling pathway. Toxicology. 304:120–131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Henson ES and Gibson SB: Surviving cell
death through epidermal growth factor (EGF) signal transduction
pathways: Implications for cancer therapy. Cell Signal.
18:2089–2097. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
31
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Darvin P, Joung YH, S P N, Kang DY, Byun
HJ, Hwang DY, Cho KH, Park KD, Lee HK and Yang YM, SP N, Kang DY,
Byun HJ, Hwang DY, Cho KH, Park KD, Lee HK and Yang YM: Sorghum
polyphenol suppresses the growth as well as metastasis of colon
cancer xenografts through co-targeting jak2/STAT3 and PI3K/Akt/mTOR
pathways. J Funct Foods. 15:193–206. 2015. View Article : Google Scholar
|
|
33
|
McMahon G: VEGF receptor signaling in
tumor angiogenesis. Oncologist. 5(Suppl 1): 3–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ariyanti AD, Sisjayawan J, Zhang J, Zhang
JQ, Wang GX, Miyagishi M, Wu SR and Kasim V: Elevating VEGF-A and
PDGF-BB secretion by salidroside enhances neoangiogenesis in
diabetic hind-limb ischemia. Oncotarget. 8:97187–97205. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang J, Liu A, Hou R, Zhang J, Jia X,
Jiang W and Chen J: Salidroside protects cardiomyocyte against
hypoxia-induced death: a HIF-1alpha-activated and VEGF-mediated
pathway. Eur J Pharmacol. 607:6–14. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Weis SM and Cheresh DA: Tumor
angiogenesis: Molecular pathways and therapeutic targets. Nat Med.
17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI
|
